Robert M Brody1, David Shimunov2, Roger B Cohen3, Alexander Lin4, John N Lukens5, Lee Hartner6, Charu Aggarwal7, Umamaheswar Duvvuri8, Kathleen T Montone9, Jalal B Jalaly10, Virginia A LiVolsi11, Ryan M Carey12, Rabie M Shanti13, Karthik Rajasekaran14, Ara A Chalian15, Christopher H Rassekh16, Steven B Cannady17, Jason G Newman18, Bert W O'Malley19, Gregory S Weinstein20, Phyllis A Gimotty21, Devraj Basu22. 1. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States; Department of Biostatistics Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Robert.Brody2@pennmedicine.upenn.edu. 2. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: David.Shimunov@pennmedicine.upenn.edu. 3. Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Roger.Cohen@pennmedicine.upenn.edu. 4. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Alexander.Lin2@pennmedicine.upenn.edu. 5. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: John.Lukens@pennmedicine.upenn.edu. 6. Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: lee.hartner@pennmedicine.upenn.edu. 7. Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: charu.aggarwal@pennmedicine.upenn.edu. 8. Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, United States. Electronic address: duvvuriu@upmc.edu. 9. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: kathleen.montone@pennmedicine.upenn.edu. 10. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: jalal.jalaly@pennmedicine.upenn.edu. 11. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: linus@pennmedicine.upenn.edu. 12. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Ryan.Carey@pennmedicine.upenn.edu. 13. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: rabie.shanti@pennmedicine.upenn.edu. 14. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Karthik.Rajasekaran@pennmedicine.upenn.edu. 15. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Ara.Chalian@pennmedicine.upenn.edu. 16. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Christopher.Rassekh@pennmedicine.upenn.edu. 17. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Steven.Cannady@pennmedicine.upenn.edu. 18. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Jason.Newman@pennmedicine.upenn.edu. 19. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: bert.omalley@umm.edu. 20. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: Gregory.Weinstein@uphs.upenn.edu. 21. Department of Biostatistics Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: pgimotty@pennmedicine.upenn.edu. 22. Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States. Electronic address: devraj.basu@uphs.upenn.edu.
Abstract
OBJECTIVES: Increasing use of transoral robotic surgery (TORS) is likely to impact outcomes for HPV+ oropharyngeal squamous cell carcinomas (OPSCCs). We aimed to describe oncologic outcomes for a large HPV+ OPSCC cohort after TORS and develop a risk prediction model for recurrence under this treatment paradigm. MATERIALS AND METHODS: 634 HPV+ OPSCC patients receiving TORS-based therapy at a single institution were reviewed retrospectively to describe survival across the entire cohort and for patients suffering recurrence. Risks for distant metastatic recurrence (DMR) and locoregional recurrence (LRR) were modeled using multivariate logistic regression analyses of case-control sub-cohorts. RESULTS: 5-year overall and recurrence-free survival were 91.2% and 86.1%, respectively. 5-year overall survival was 52.5% following DMR and 83.3% after isolated LRR (P = .01). In case-control analyses, positive surgical margins were associated with DMR (adjusted OR 5.8, CI 2.1-16.0, P = .001), but not isolated LRR, and increased DMR risk 4.2 fold in patients with early clinical stage disease. By contrast, LRR was associated with not receiving recommended adjuvant therapy (OR 13.4, CI 6.3-28.5, P < .001). CONCLUSIONS: This study sets a benchmark for oncologic outcomes from HPV+ OPSCC after TORS-based therapy. Under this treatment paradigm, margins are relevant for assessing lethal recurrence risk during clinical trial design and post-treatment surveillance.
OBJECTIVES: Increasing use of transoral robotic surgery (TORS) is likely to impact outcomes for HPV+ oropharyngeal squamous cell carcinomas (OPSCCs). We aimed to describe oncologic outcomes for a large HPV+ OPSCC cohort after TORS and develop a risk prediction model for recurrence under this treatment paradigm. MATERIALS AND METHODS: 634 HPV+ OPSCC patients receiving TORS-based therapy at a single institution were reviewed retrospectively to describe survival across the entire cohort and for patients suffering recurrence. Risks for distant metastatic recurrence (DMR) and locoregional recurrence (LRR) were modeled using multivariate logistic regression analyses of case-control sub-cohorts. RESULTS: 5-year overall and recurrence-free survival were 91.2% and 86.1%, respectively. 5-year overall survival was 52.5% following DMR and 83.3% after isolated LRR (P = .01). In case-control analyses, positive surgical margins were associated with DMR (adjusted OR 5.8, CI 2.1-16.0, P = .001), but not isolated LRR, and increased DMR risk 4.2 fold in patients with early clinical stage disease. By contrast, LRR was associated with not receiving recommended adjuvant therapy (OR 13.4, CI 6.3-28.5, P < .001). CONCLUSIONS: This study sets a benchmark for oncologic outcomes from HPV+ OPSCC after TORS-based therapy. Under this treatment paradigm, margins are relevant for assessing lethal recurrence risk during clinical trial design and post-treatment surveillance.
Authors: Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le Journal: Lancet Date: 2018-11-15 Impact factor: 79.321
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Daniel J Ma; Katharine A Price; Eric J Moore; Samir H Patel; Michael L Hinni; Joaquin J Garcia; Darlene E Graner; Nathan R Foster; Brenda Ginos; Michelle Neben-Wittich; Yolanda I Garces; Ashish V Chintakuntlawar; Daniel L Price; Kerry D Olsen; Kathryn M Van Abel; Jan L Kasperbauer; Jeffrey R Janus; Mark Waddle; Robert Miller; Satomi Shiraishi; Robert L Foote Journal: J Clin Oncol Date: 2019-06-04 Impact factor: 44.544
Authors: Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre Journal: Head Neck Date: 2005-10 Impact factor: 3.147
Authors: Kyle M Hatten; Bert W O'Malley; Andres M Bur; Mihir R Patel; Christopher H Rassekh; Jason G Newman; Steven B Cannady; Ara A Chalian; Benjamin L Hodnett; Alexander Lin; John N Lukens; Roger B Cohen; Joshua M Bauml; Kathleen T Montone; Virginia A Livolsi; Gregory S Weinstein Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-03-01 Impact factor: 6.223
Authors: Mitchell Machtay; Jennifer Moughan; Andrew Trotti; Adam S Garden; Randal S Weber; Jay S Cooper; Arlene Forastiere; K Kian Ang Journal: J Clin Oncol Date: 2008-06-16 Impact factor: 44.544
Authors: Kalyani Sonawane; Ryan Suk; Elizabeth Y Chiao; Jagpreet Chhatwal; Peihua Qiu; Timothy Wilkin; Alan G Nyitray; Andrew G Sikora; Ashish A Deshmukh Journal: Ann Intern Med Date: 2017-10-17 Impact factor: 25.391